Esperion sues Daiichi Sankyo Europe over $300M milestone payment dispute

Esperion Therapeutics, Inc.

Filed amended complaint seeking declaration that DSE must pay $300M regulatory milestone upon cardiovascular risk reduction label.
DSE informed Esperion on March 8, 2023 it would not make payment, citing MACE-4 result below 15%.
Agreement requires payment for >20% risk reduction based on CLEAR Outcomes study; DSE's interpretation allegedly contradicts plain terms.
Esperion claims DSE's repudiation caused 54% stock drop and is bad-faith attempt to renegotiate.
Court in Southern District of New York; expedited declaratory judgment sought.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.